Anti-Abatacept Antibodies
-
Bioanalytical Antibodies
-
Antibodies for Bioanalysis and Drug Monitoring
-
Our Anti-Biotherapeutic Antibodies
- Anti-Abatacept Antibodies
- Anti-Adalimumab Antibodies
- Anti-Aflibercept Antibodies
- Anti-Alemtuzumab Antibodies
- Anti-Atezolizumab Antibodies
- Anti-Avelumab Antibodies
- Anti-Belatacept Antibodies
- Anti-Belimumab Antibodies
- Anti-Benralizumab Antibodies
- Anti-Bevacizumab Antibodies
- Anti-Brentuximab Antibodies
- Anti-Burosumab Antibodies
- Anti-Canakinumab Antibodies
- Anti-Cemiplimab Antibodies
- Anti-Certolizumab Antibodies
- Anti-Cetuximab Antibodies
- Anti-Daratumumab Antibodies
- Anti-Denosumab Antibodies
- Anti-Dulaglutide Antibodies
- Anti-Dupilumab Antibodies
- Anti-Durvalumab Antibodies
- Anti-Eculizumab Antibodies
- Anti-Elotuzumab Antibodies
- Anti-Emicizumab Antibodies
- Anti-Etanercept Antibodies
- Anti-Evolocumab Antibodies
- Anti-Golimumab Antibodies
- Anti-Guselkumab Antibodies
- Anti-Ixekizumab Antibodies
- Anti-Infliximab Antibodies
- Anti-Ipilimumab Antibodies
- Anti-Natalizumab Antibodies
- Anti-Nivolumab Antibodies
- Anti-Nirsevimab Antibodies
- Anti-Obinutuzumab Antibodies
- Anti-Ocrelizumab Antibodies
- Anti-Omalizumab Antibodies
- Anti-Palivizumab Antibodies
- Anti-Panitumumab Antibodies
- Anti-Pembrolizumab Antibodies
- Anti-Pertuzumab Antibodies
- Anti-Ramucirumab Antibodies
- Anti-Ranibizumab Antibodies
- Anti-Risankizumab Antibodies
- Anti-Rituximab Antibodies
- Anti-Romosozumab Antibodies
- Anti-Sarilumab Antibodies
- Anti-Secukinumab Antibodies
- Anti-Tocilizumab Antibodies
- Anti-Trastuzumab Antibodies
- Anti-Tremelimumab Antibodies
- Anti-Ustekinumab Antibodies
- Anti-Vedolizumab Antibodies
- Anti-Isatuximab Antibodies
-
Our Anti-Biotherapeutic Antibodies
-
Antibodies for Bioanalysis and Drug Monitoring
s
s
s
Antibodies for bioanalysis and drug monitoring of abatacept and biosimilars
Develop highly selective and sensitive PK and ADA assays for abatacept (Orencia) using our range of ready-made antibodies.
- Recombinant antibodies specific to abatacept CTLA-4 domain
- Fully human format for surrogate positive control or calibrator
- Sequence defined, well characterized reagents with secure supply
- Stringent quality control for batch-to-batch consistency
- Tested for use with mouse anti-human CTLA-4 (CD152) antibody
Table 1. Antibodies Specific to Abatacept and CTLA-4.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
|---|---|---|---|---|---|---|
|
Abatacept (CTLA-4 domain) |
HCA335 |
AbD37058ia |
Human IgG1 |
1 |
PK bridging ELISA (detection) |
|
| TZA0143P | AbD37058pap | Fab2-FH-X22-HRP2 | 1 | PK bridging ELISA (detection) | Order TZA0143P | |
|
HCA336 |
AbD37065ia |
Human IgG1 |
6 |
ADA control |
||
|
CTLA-4 (CD152) |
MCA1724 |
BNI3 |
Mouse IgG2a |
n.d. |
PK bridging ELISA (capture) |
* Affinity measured in the monovalent Fab format.
1 Fab-FH= Monovalent Fab antibody DYKDDDDK- and His-6-tags.
2Fab2-FH-X22-HRP = Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags, and Fab-SpyTag coupled to HRP-conjugated BiCatcher.
Anti-Abatacept Antibodies
Abatacept is a recombinant fusion protein drug consisting of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), linked to a modified Fc portion of human immunoglobulin G1 (hIgG1). Our anti-abatacept antibodies inhibit the binding of the drug to its target CD80. Human Anti-Abatacept Antibody, clones AbD37058ia (HCA335) and AbD37058pap (TZA0143P), can be used for detection in a pharmacokinetic (PK) bridging ELISA to measure free drug, paired with Mouse Anti-Human CTLA-4 (CD152) Antibody (MCA1724) as capture reagent. HCA335, HCA336, and MCA1724 are suitable as surrogate positive controls or calibrators for an anti-drug antibody (ADA) assay.
ELISA Protocols to Get You Started
PK Bridging ELISA
Fig. 1. Abatacept PK bridging ELISA using antibodies MCA1724 and HCA335.
Schematic image of PK bridging ELISA measuring free drug. Monoclonal capture antibody, Ig format (gray), fusion protein drug (gold-green), anti-drug detection antibody, Ig format (blue) labeled with HRP.
Fig. 2. Abatacept PK bridging ELISA using antibodies MCA1724 (capture) and TZA0143P (detection).
Schematic image of PK bridging ELISA measuring free drug. Monoclonal capture antibody, Ig format (gray), fusion protein drug (gold-green), detection antibody, Fab format (purple) labeled with HRP.
ADA Bridging ELISA
Fig. 3. Abatacept ADA bridging ELISA using antibody HCA335, HCA336, or MCA1724.
Schematic image of ADA bridging assay. Fusion protein drug as capture and detection reagent labeled with HRP (gold-green), monoclonal anti-drug antibody, Ig format (blue).
Resources
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.